Kalbe Farma stock: UOB cites IDR 770 for Kalbe Farma stock

Published on 10/19/2026 at 15:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Semester I 2026 revenue reached IDR 19.47 trillion, up 14.06 percent year on year. Kalbe Farma stock costs EUR 0.03 on October 19, 2026, unchanged.

Business growth and key dates

UOB cited IDR 770 as a technical buy level on October 9, 2026.
Semester I 2026 revenue reached IDR 19.47 trillion, up 14.06 percent year on year.
Kalbe Farma stock traded at EUR 0.03 at Lang & Schwarz on October 19, 2026 at 3:31 p.m. CEST and was unchanged.
The next earnings date is November 3, 2026.

Kalbe Farma, ID1000125107, Illustration mit AI erstellt.

Kalbe Farma (ISIN ID1000125107) had a technical buy level of IDR 770 in a report dated October 9, 2026, from UOB Kay Hian. Against the Jakarta price of IDR 655 on October 19, 2026, that level stood 17.56 percent higher. At 3:31 p.m. CEST, Kalbe Farma stock was trading at EUR 0.03 at Lang & Schwarz, unchanged on the quote.

Revenue grows faster than profit

Kalbe Farma reported first-half 2026 revenue of IDR 19.47 trillion, up 14.06 percent from IDR 17.07 trillion in the same period of 2025, according to DiaNet Indonesia on October 8, 2026. Net income nevertheless fell to IDR 1.91 trillion from IDR 1.97 trillion, a decline of 3.05 percent. The contrast puts cost control alongside sales growth in the next reporting cycle.

The share sits below its yearly high

On October 19, 2026, the Jakarta-listed stock was at IDR 655, down 2.96 percent from IDR 675. The session range was IDR 630 to IDR 670, while volume reached 174,699,500 shares against an average of 73,674,590. The price stood 3.97 percent above the 52-week low of IDR 630 and 51.30 percent below the 52-week high of IDR 1,345.

Valuation and reporting date

Kalbe Farma had a market capitalization of IDR 29.6 trillion, a price-to-earnings ratio of 8.23 and a trailing dividend yield of 0.03 percent as of October 19, 2026. Investing.com lists November 3, 2026 as the next earnings date and shows an average analyst target of IDR 1,119.

Comparison with peers

Kalbe Farma (Jakarta, IDR): unchanged, price-to-earnings ratio 8.23, market capitalization IDR 29.6 trillion
Sido Muncul (Jakarta, IDR): minus 6.13 percent, price-to-earnings ratio 9.35, market capitalization IDR 9.0 trillion
Tempo Scan Pacific (Jakarta, IDR): minus 4.45 percent, price-to-earnings ratio 7.19, market capitalization IDR 10.6 trillion

The euro quote holds steady

The euro quote remained at EUR 0.03 during the afternoon, while the Jakarta listing closed at IDR 655. The different quotation currencies describe separate market views and are not combined into one performance figure. Kalbe Farma was trading at EUR 0.03 at Lang & Schwarz on October 19, 2026 at 3:31 p.m. CEST, unchanged on the quote. The further course of trading is shown by the continuously updated real-time quote of Kalbe Farma stock.